Neurotrauma 2019 | Quanterix

COVID-19
Simoa® Technology
Therapeutic Areas
Neurology Oncology Immunology/Inflammation Infectious Disease Cardiology
Products & Services
Simoa® Assay KitsReady-to-use Simoa® assay kits compatible with Quanterix instruments Simoa® SARS CoV-2 Antigen Assay (EUA)COVID-19 antigen test for qualitative detection of N protein antigen and permitted for use under FDA Emergency Use Authorization HD-X Analyzer™Our flagship automated immunoassay analyzer offering ultrasensitive biomarker measurement SR-X™ Biomarker Detection SystemBenchtop digital immunoassay platform delivering ultrasensitive biomarker detection in a compact instrument SP-X Imaging and Analysis System™Robust circulating biomarker detection in a benchtop multiplex immunoassay platform 2470 ArrayerFully automated microarray printer powered by proprietary soft touch deposition technology Simoa® Accelerator LaboratoryFull-service center for biomarker testing services and custom immunoassay development Uman NF-Light™NfL ELISA kits and antibodies for the detection of neurofilament light chain Homebrew – Custom Assay DevelopmentUltrasensitive immunoassay development solution providing flexibility for specialized research applications
Support & Resources
Customer Care & Technical Support Safety Data Sheets & Cert. of Analysis Product Brochures Whitepapers & App Notes Publications And Posters Conferences Webinars
Media Center
Press Releases Videos & Recordings In The News Blog
Company
Meet the Management Team Meet the Global Sales Team
Contact Us

Careers
Investors
Customer Portal
Search

back to conferences

Neurotrauma 2019

date

30 June - 2 July, 2019

location

Pittsburgh, PA

Booth 16

More information

Share this page

stay tuned

Subscribe to our newsletter

info@quanterix.com

900 Middlesex TPKE
Billerica, MA 01821
USA

Investor Portal
Customer Portal
Contact Us

Terms and Conditions
Privacy Shield Statement

© 2021 Quanterix All rights reserved.

Privacy Policy

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

Agree Learn more